Abstract Search

ea0056p606 | Obesity | ECE2018

Differences in percentage of weight loss and secondary effects after one and two months of treatment with liraglutide versus naltrexone/bupropion

Voltas Arribas Beatriz , Juan Carlos Sanchez , Garcia Juan Carlos Ferrer , Fullana Ana Artero , Revert Pablo Sanz , Alacid Cristian Marco , Merseguer Mario Lopez

Introduction: Obesity is one of the most prevalent health problems in our society. The marketing of Liraglutide and the Naltrexone/Bupropion combination has been given the green light.Objectives: To analyze the differences in a series of 19 patients assigned to treatment with Liraglutide or Naltrexone/Bupropion.Material and methods: A descriptive analysis was carried out using Stata. 19 patients were included, 9 were treated with L...

0 shares

ea0090ep437 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Real-world effectiveness analysis of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus

Ferrer Garcia Juan Carlos , Albalat-Galera Raquel , Moya Victor Atienza , Hernandez Jessica Sanchez , Palomar Luis Arribas , Casamayor Ignacio Ramos , Fullana Ana Artero , Blanco Cintia Gonzalez , Portilla Ana Jimenez , Juan Carlos Sanchez

Background and Objective: Semaglutide, a glucagon-like peptide 1 (GLP1a) receptor agonist, reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus (DM2). An oral version of semaglutide is now available, and patients may prefer it to the subcutaneous form. Our objective was to compare the effectiveness and safety of both formulations in real life.Methods: Retrospective real-world efficacy analysis including aGLP1-...

2 shares

Endocrine Abstracts

Differences in percentage of weight loss and secondary effects after one and two months of treatment with liraglutide versus naltrexone/bupropion

Real-world effectiveness analysis of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus

BiosciAbstracts